Merck KGaA reaffirmed its strong performance in the healthcare sector in its FY 2024 earnings report, but provided little additional information on ongoing acquisition talks with SpringWorks ...

Merck KGaA (MKGAY) said in its annual report this morning: “On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics (SWTX), Inc ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Barclays continues to see limited regulatory risk for Merck KGaA’s potential buyout of SpringWorks. It has an Overweight rating on SpringWorks with a $63 price target See what stocks are ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline ...

A much-needed pipeline boost could come from a potential acquisition of cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., for which Merck said last month it was in advanced talks.

SpringWorks Therapeutics portfolio features ... Therefore, while it’s nice to see Merck KGaA’s interest in SWTX for a potential acquisition deal, I also reckon it adds volatility to SWTX ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ ...

Merck KGaA is reportedly in discussions to acquire SpringWorks, which has one other approved product and three experimental candidates. Human Technopole is recruiting an outstanding Group Leader ...

Merck & Co. Inc. (MRK): Revenue from ... Jefferies singled out Structure Therapeutics Inc. (GPCR), Insmed Inc. (INSM) and SpringWorks Therapeutics Inc. (SWTX) Another biotech stock worth watching ...